首页> 外文期刊>Ethiopian journal of health sciences >Mutations of rpob Gene Associated with Rifampin Resistance among Mycobacterium Tuberculosis Isolated in Tuberculosis Regional Reference Laboratory in Northeast of Iran during 2015–2016
【24h】

Mutations of rpob Gene Associated with Rifampin Resistance among Mycobacterium Tuberculosis Isolated in Tuberculosis Regional Reference Laboratory in Northeast of Iran during 2015–2016

机译:2015-2016年在伊朗东北部结核病区域参考实验室分离的结核分枝杆菌 rpob 基因突变与利福平耐药性相关

获取原文
           

摘要

Background Drug resistance is a leading concern in control of TB. Resistance against rifampin as one of the most important drugs in the treatment of Mycobacterium tuberculosis is caused by mutations in the 81-base pair region of the rpoB gene encoding the β-subunit of RNA polymerase. This study aimed to characterize the mutations in the rpoB gene associated with rifampin resistance among M. tuberculosis. Methods This study was conducted on referred samples of patients who did not respond to anti-TB treatment, in Tuberculosis Regional Reference Laboratory at Shariati Hospital. Drug susceptibility of M. tuberculosis isolates was surveyed using a proportional method on LJ medium. The isolates with resistant to rifampin were reconfirmed and then the rpoB gene was amplified and sequenced. Results Among 27 resistant cases, 8, 11 and 8 people were from Iran, Afghanistan, and Turkmenistan, respectively. In 26 out of 27 isolates, rpoB gene mutations were observed. The most prevalent mutations belonged to the codon 53. The most prevalent mutations belonged to the TCG (Ser) 531TTG (leu) with prevalence 51.8% (n=14), and GAC (Asp)516TAC (Tyr), CAC (His) 526GAC (Asp) and CAC (His) 526TAC(Tyr) mutations with prevalence 14.8%(n=4). Twenty-three isolates had just one mutation. Conclusion The use of rpoB gene sequencing led to the lack of the need for growth of the organism in the culture medium, the direct use of clinical samples, reduction of biological risks and a detection about 96.3% of MDR TB cases lowering the cost of the treatment.
机译:背景耐药性是控制结核病的首要问题。作为治疗结核分枝杆菌最重要的药物之一,对利福平的耐药性是由编码RNA聚合酶β亚基的rpoB基因的81个碱基对区域的突变引起的。这项研究旨在表征结核分枝杆菌中与利福平耐药相关的rpoB基因突变。方法本研究是在Shariati医院的结核病区域参考实验室中对抗结核治疗无反应的患者参考样本进行的。在LJ培养基上使用比例法调查了结核分枝杆菌的药物敏感性。再次确认对利福平具有抗性的分离株,然后扩增和测序rpoB基因。结果在27例抗药性病例中,分别有8、11和8人来自伊朗,阿富汗和土库曼斯坦。在27株分离物中的26株中,观察到rpoB基因突变。最普遍的突变属于密码子53。最普遍的突变属于TCG(Ser)531TTG(leu),患病率51.8%(n = 14),GAC(Asp)516TAC(Tyr),CAC(His)526GAC (Asp)和CAC(His)526TAC(Tyr)突变,患病率为14.8%(n = 4)。 23个分离株仅有一个突变。结论使用rpoB基因测序导致无需在培养基中生长生物,无需直接使用临床样品,降低了生物风险,检出约96.3%的MDR TB病例降低了成本。治疗。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号